Goldman Sachs Group Inc Stock Price, News & Analysis

Ajax Therapeutics, a biopharmaceutical company, raised $95 million in Series C financing to advance their Type II JAK2 Inhibitor, AJ1-11095, into clinical trials for myelofibrosis treatment. The financing was led by Goldman Sachs Alternatives and included several new and existing investors. AJ1-11095 is designed to provide better efficacy and disease modification compared to current JAK2 inhibitors. The company aims to address unmet needs in treating myeloproliferative neoplasms (MPNs) with innovative therapies.

Bixby Land Company closed its Bixby Industrial Fund I, offering existing investors liquidity and extending duration for a portfolio of industrial properties in California, Arizona, and Georgia. The fund, with equity investors like Vintage Strategies at Goldman Sachs Alternatives and Ares Management Real Estate Secondaries fund, aims for value-add returns over a 5-7 year horizon.

Goldman Sachs BDC, Inc. reported strong financial results for the first quarter of 2024, with net investment income per share of $0.55 and adjusted net investment income per share of $0.54. Earnings per share were $0.39, and the net asset value per share decreased slightly to $14.55. The company's investment portfolio comprised mainly of senior secured debt, with total investments at fair value and commitments amounting to $3,954.8 million. The Company also declared a quarterly dividend of $0.45 per share and closed a public offering of $400.0 million aggregate principal amount of unsecured notes due 2027. Despite some investments on non-accrual status, the Company's financial position remains strong.

Transcendia Holdings, Inc. announces a recapitalization transaction providing $114 million in new capital, eliminating over $200 million in debt, and strengthening its competitive position. Industrial Opportunity Partners becomes majority shareholder with Goldman Sachs Asset Management retaining a significant minority stake. The transaction supports Transcendia's growth strategy, cost structure improvements, facility optimization, and expansion into new markets.

Sun European Partners, LLP affiliate agrees to sell leading UK environmental risk reduction specialist, Adler & Allan, to Goldman Sachs Alternatives. The acquisition is expected to close in the next few months pending approvals. Adler & Allan, founded in 1926, operates in Environmental, Energy, and Water Services, with a focus on sustainability and climate transition. Sun European's buy & build strategy enhanced growth and value creation through strategic add-ons and diversification into renewable energy services. Goldman Sachs aims to accelerate growth organically and through targeted acquisitions.